Club XQuizIT

presents

PLACEMENT gYAAN

Zydus Cadilla:
Zydus Cadila is a fully integrated, global healthcare provider, with strengths all along
the pharmaceutical value chain. With a core competence in the field of healthcare,
Zydus Cadila provides total healthcare solutions ranging from formulations, active
pharmaceutical ingredients and animal healthcare products to wellness products.
Recently, the group launched Exemptia, the worlds first biosimilar for Adalimumab,
the largest selling therapy worldwide for inflammatory arthritis. Zydus is also the only
Indian pharma company to launch its own patented NCE Lipaglyn, the worlds first
drug to be approved for the treatment of diabetic dyslipidemia.
The groups origin can be traced to 1952 when it was founded by Late Mr.
Ramanbhai B. Patel, a first-generation entrepreneur and one of the stalwarts of the
Indian Pharmaceutical Industry. In 1995, the group restructured its operations and
Cadila Healthcare came into being under the aegis of the Zydus group. Zydus
Cadila, today, is spearheaded by Mr. Pankaj R. Patel, the Chairman and Managing
Director of the group.
From a turnover of Rs. 250 crores in 1995, the group posted revenues of over Rs.
8600 crores in FY15. The group had posted a turnover of Rs. 4600 crores in FY 11,
making it a billion dollar company. It aims to be a leading global healthcare provider
with a robust product pipeline and aspires to post revenues of Rs. 10000 crore by
2015-16 and be a research-based pharmaceutical company by 2020.

Zydus Wellness:
Zydus Wellness Limited was incorporated as Carnation NutraAnalogue Foods
Limited. Initially the company was engaged in the business of manufacturing, buying
and selling of all types of health food products, low fat, low cholesterol including table
margarine, cheese, butter and substitute products. The name of the company has
been changed from 'Carnation NutraAnalogue Foods Limited' to 'Zydus Wellness
Limited' with effect from January 5, 2009.
On march 17,2006, Zydus Cadila acquired 834,000 equity shares of Rs 10 each
representing about 14.96% of the fully paid up equity voting capital of the company
at a price of Rs 144.82 per share. Further Zydus Cadila came with a voluntary open
offer to acquire up to 11,15,020 fully paid up equity shares of the face value Rs 10
each representing 20% of the paid up equity share capital of the company at a price
of Rs 150 per share in March 2007.
The Consumer Division of Zydus Cadila was envisioned to promote healthy living
by anticipating emerging and daytoday needs in dietetic/health foods, and

personal care by offering healthier choices to the consumer. Health and wellness
have been identified as emerging opportunity areas in consumer healthcare and a
key focus area for the business. The consumer division aims to empower individuals
to take increasing responsibility for ones health by adopting healthy eating and living
habits and lifestyles. The Division markets products under two major groups the
Sugar Free range and the EverYuth range.
The acquisition has strengthened the divisions offerings to the healthconscious
consumers, as a pioneer in low calorie/dietetic products and functional/health foods.
With the convergence of healthcare, nutrition, wellness and cosmeceuticals, only
those companies with the ability to innovate, expand market reach and offer niche
products in this domain will have a clear advantage in the marketplace. Zydus
Wellness Ltd., has strong credentials and is best placed to make early inroads in this
emerging market and add experiences that enrich life.
Product range of the company: It is a pioneer in the low calorie sweetener
segment and a trendsetter in skincare products. It acquired Nutralite, Indias largest
selling margarine in FY 0607 and revamped it. Nutralite grew by over 25% yoy
post acquisition.
Sugar FreeIndias largest selling sugar substitute with market share of over 82%.
Everyuth range of skincare products are also category leaders. Recently launched
Menza skincare range for men.

Functional Health Foods and Dietary Products:

In the health foods segment, the Consumer Division is a pioneer in offering healthier
dietary options to the consumers with the Sugar Free and Nutralite range of
products.
Sugar Free Gold is the largest selling aspartame based low calorie sugar substitute
in India with market share of over 75%. Sugar Free Natura is the latest new
generation zero calorie sugar substitute made from sucralose a sugar derivative.
Sugar Free Dlite is a low calorie healthy drink fortified with electrolytes, vitamins and
just 10 calories. It is available as powder soft drink as well as in a ready to drink
form.
Nutralite is a healthy cholesterolfree butter substitute (table margarine), and is the
largest selling table margarine in India.

In 2010 they launched Sugar Free Natura Flavored sachets in Lemon Mint and
Ginger Masala flavours to enhance the consumer experience and offer a wider
choice to the customers.
In September 2010, the company extended their niche product basket with the
launch of Sugar Free Mints. The company is planning to launch various value added
products to provide the consumers, the Sugar Free experience in various forms. The
company is setting up a manufacturing facility in Sikkim to cater to the growing
demand of Sugar Free and EverYuth, which are outsourced at present.
Speciality Skincare Products
In the skincare segment, the EverYuth brand enjoys the distinction of being a
'skincare brand from a healthcare company'. Enriched with the power of natural
ingredients, EverYuth has a strong presence in advanced skincare segments like
soapfree face washes, face masks, skin exfoliators amongst others.
The EverYuth range also includes speciality dermatologically tested skincare
solutions for sun protection, pigmentation, acne and aging under the recently
launched EverYuth Derma Care range.
Fruit Face Wash
Enriched with ingredients like fruit (apple) extracts and multivitamin complex, the
100% soapfree Fruit Face Wash washes away dirt from the innermost pores. It
helps the skin regain moisture and essential nutrients lost due to the exposure to the
harsh environment, leaving the skin refreshed with a soothing afterfeel.
EverYuth Sun Care Sun Block Lotion SPF 30++
Unlike other lotions, this Sun Block Lotion has SPF 30++ (Boots star rating) that
ensures double protection from both UVA and UVB rays. Its unique nongreasy
formula prevents your skin from darkening and premature ageing, while leaving it
moisturised with a soothing feel.
In Feb 2014 Zydus Cadila received the final approval from the USFDA to market
Clonidine Hcl Injection 0.1 and 0.5 mg/ml, 10 ml. The group has so far filed 216
ANDAs since the commencement of filing process in FY 200304.

Product Portfolio:
EverYuth:
Face wash
Facial Masks (peel off, packs)
Scrubs
Sun blocks
Winter care - (body lotion and cream)
Cleanser and Toner
Soaps
Men skin care - (face washes, sun block, moisturizer, & scrub)
Sugar Free:
Sugar Free Gold
Sugar Free Natura
Nutralite
Actilife

Vision:
We bring Wellness to your Life.
"We will create new experiences by our products that will nourish, nurture and
energies your life We shall lead the way through innovation".

Key People
Amit B Jain

Chief Financial Officer

B M Hegde

Director

Dhaval N Soni

Co. Secretary & Compl. Officer

Dhaval N Soni

Secretary

Ganesh N Nayak

Director

H Dhanrajgir

Director

Indiraben J Parikh

Director

Sharvil P Patel

CEO

Sharvil P Patel

Chairman

Tarun Arora

Whole Time Director & COO

Corporate Social Responsibility

Good health, happiness, joy, growth, togetherness, discovery, learning, exploration,
evolution, transformation, aspirations, are all intrinsically linked with life. Zydus is
dedicated to all these dimensions. Zydus Srishti, the groups CSR programme, is
about reaching out to make a difference in a myriad ways in the areas of Health
Swaasthya, Education Shiksha, Research Shodh and Outreach Saath.
Through these initiatives, the group reaches out to the community that it forms a part
of, finding new expressions for its mission to create healthier communities globally.
The group has forged meaningful partnerships with its key stakeholders both internal
and external, partners in progress and the community at large.

Important Awards
The Zydus group was one amongst the top five companies worldwide at the FT
ArcelorMittal Boldness in Business Awards 2014 in the Developing Markets
category and was declared as the Emerging Company of the Year by the
Economic Times Awards for Corporate Excellence 2010. In January 2014, Mr.
Pankaj Patel was conferred the India Innovator Award 2013 at the India Business
Leaders Awards instituted by CNBC

Balance Sheet as on 31th March 2015

Standalone Balance Sheet

Sources Of Funds
Total Share Capital
Equity Share Capital
Share Application Money
Preference Share Capital
Reserves
Networth
Secured Loans
Unsecured Loans
Total Debt
Total Liabilities

in Rs. Cr.
Mar '15 Mar '14 Mar '13 Mar '12 Mar '11

39.07
39.07
0
0
366.97
406.04
0
0
0
406.04

39.07
39.07
0
0
286.49
325.56
0
0
0
325.56

39.07
39.07
0
0
217.47
256.54
0
0
0
256.54

39.07
39.07
0
0
147.79
186.86
0
0
0
186.86

39.07
39.07
0
0
102.82
141.89
0
0
0
141.89

Application Of Funds
Gross Block
Less: Revaluation
Reserves
Less: Accum. Depreciation
Net Block
Capital Work in Progress
Investments
Inventories
Sundry Debtors
Cash and Bank Balance
Total Current Assets
Loans and Advances
Fixed Deposits
Total CA, Loans &
Advances
Deferred Credit
Current Liabilities
Provisions
Total CL & Provisions
Net Current Assets
Miscellaneous Expenses

63.5

67.67

63.58

62.74

61.06

0
19.08
44.42
0
100.27
4.11
0.33
294.79
299.23
7.06
0

0
14.54
53.13
0
145.65
4.63
0.23
163.93
168.79
5.73
0

0
12.2
51.38
0
95.73
6.74
0.46
146.15
153.35
5.08
0

0
9.97
52.77
0
47.71
6.04
0.36
127.17
133.57
6.57
0

0
7.87
53.19
0.31
39.7
17.5
1.17
87.76
106.43
6
0

306.29
0
16.38
28.56
44.94
261.35
0

174.52
0
20.12
27.62
47.74
126.78
0

158.43
0
21.26
27.74
49
109.43
0

140.14
0
30.8
22.96
53.76
86.38
0

112.43
0
44.59
19.15
63.74
48.69
0

Statement of Profit and Loss for the year end March 31, 2015
Standalone Profit & Loss
account

Income
Sales Turnover
Excise Duty
Net Sales
Other Income
Stock Adjustments
Total Income
Expenditure
Raw Materials
Power & Fuel Cost
Employee Cost
Other Manufacturing
Expenses
Selling and Admin
Expenses

in Rs. Cr.
Mar
Mar
'13
'12

Mar
'15

Mar
'14

Mar
'11

221.47
2.36
219.11
20.45
-0.26
239.3

203.25
0
203.25
11.69
-2.45
212.49

213.01
0
213.01
13.89
0.07
226.97

253.59
0
253.59
8.81
-11.65
250.75

336.37
0
336.37
7.21
4.58
348.16

61.19
1.51
15.78

56.77
1.3
12.95

64.91
1.26
11.96

82.59
0
10.07

125.96
0
18.3

Miscellaneous Expenses
Preoperative Exp
Capitalised
Total Expenses
Operating Profit
PBDIT
Interest
PBDT
Depreciation
Other Written Off
Profit Before Tax
Extra-ordinary items
PBT (Post Extra-ord Items)
Tax
Reported Net Profit
Total Value Addition
Preference Dividend
Equity Dividend
Corporate Dividend Tax
Per share data (annualised)
Shares in issue (lakhs)
Earning Per Share (Rs)
Equity Dividend (%)
Book Value (Rs)

47.55

48.44

47.14

77.18

112.45

0
126.03

0
119.46

0
125.27

0
169.84

0
256.71

92.82
113.27
0
113.27
4.55
0
108.72
0
108.72
-0.23
108.95
64.84
0
23.44
4.77

81.34
93.03
0
93.03
2.43
0
90.6
0
90.6
-5.85
96.45
62.69
0
23.44
3.99

87.81
101.7
0
101.7
2.37
0
99.33
0
99.33
2.22
97.11
60.36
0
23.44
3.99

72.1
80.91
0
80.91
2.3
0
78.61
0
78.61
10.93
67.68
87.25
0
19.54
3.17

84.24
91.45
0
91.45
1.49
0
89.96
0
89.96
30.48
59.48
130.75
0
15.63
2.54

390.72
27.88
60
103.92

390.72
24.69
60
83.32

390.72
24.85
60
65.66

390.72
17.32
50
47.82

390.72
15.22
40
36.31

SWOT Analysis
Strengths
-existing distribution and sales networks
-experienced business units
-barriers of market entry
-high profitability and revenue
-monetary assistance provided
Weaknesses
-productivity
-future profitability
-tax structure
-high loan rates are possible
Opportunities

-new markets
-venture capital
Threats
-tax changes
-financial capacity
-external business risks

Recent Press Releases

November, 2015
Zydus launches Tenglyn, the most affordable gliptin for diabetics in India
Zydus announces clinical
Hypertriglyceridemia in USA

trials

of

Saroglitazar

in

patients

with

October, 2015
Zydus Cadilas Net Profit up by 41% in Q2
Zydus Wellness registers a Net Profit of Rs. 291 mn in Q2
August, 2015
Zydus Cadila Q1 Net Profit up by 47%
Zydus receives final approval for Amiloride Hcl Tablets
News:
Zydus Wellness managing director Elkana N. Ezekiel resigns::: livemint.com
Zydus Wellness Q1 net up over 14% at Rs 19.52 crore:::Moneycontrol News

References
http://zyduscadila.com/
http://economictimes.indiatimes.com/topic/Zydus-Cadila
http://www.swotanalysis24.com/swot-z/122336-swot-analysis-zydus-cadila.html
moneycontrol.com
Zydus Wellness Official Website
NDTV Profit

Severe